Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 0466

Next Previous
Drug Profile

AZD 0466

Alternative Names: AZD-0466

Latest Information Update: 15 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Starpharma
  • Class Antineoplastics; Dendrimers; Drug conjugates; Small molecules
  • Mechanism of Action Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 05 Apr 2024 Efficacy, adverse events, pharmacokinetics and pharmacodynamics data from a phase I trial in Non-Hodgkin's lymphoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Chronic Lymphocytic Leukemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 17 Aug 2023 AstraZeneca terminates a phase-I/II trial in Non-Hodgkin's lymphoma (In adults, In the elderly, Monotherapy, Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia, Canada, France, Germany, Italy, Portugal, South Korea, Spain and USA due to safety reasons (IV) (NCT05205161) (EudraCT2021-003410-39)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top